Justin Stebbing: Activity of botensilimab/balstilimab in patients with metastatic colon cancer

Justin Stebbing shared a post on LinkedIn:

“Really interesting paper out today am part of in Nature Medicine showing activity of botensilimab/balstilimab, a new immunotherapy combination, in heavily pre-treated patients with metastatic colon cancer. Thanks to everyone involved, and all the patients.”

Read further.
Source: Justin Stebbing/LinkedIn 

Justin Stebbing is a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at Anglia Ruskin University (ARU), Cambridge. He was appointed the first NIHR oncology professor in 2011. He is editor-in-chief of Nature’s cancer journal Oncogene. Prof. Stebbing has published over 700 peer-reviewed papers in leading academic journals. He is a member of the American Society for Clinical Investigation, a fellow of the Royal College of Physicians, and the Royal College of Pathologists, and sits on many advisory boards. He is on the Editorial Board of OncoDaily.